• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Aclaris Therapts (NQ: ACRS )

    1.190 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, Aug 16, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 502
    Open 1.190
    Bid (Size) 1.160 (6)
    Ask (Size) 1.190 (21)
    Prev. Close 1.190
    Today's Range 1.190 - 1.190
    52wk Range 0.5902 - 8.275
    Shares Outstanding 71,344,557
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Aclaris Therapeutics And 3 Other Stocks Under $2 Insiders Are Buying
    Via Benzinga
    3 Beaten Down Pharmaceuticals With Catalysts for Higher Prices
    Beaten-down stocks offer value to investors, but not all are worth buying. This is a look at three biopharma at long-term lows with catalysts for higher prices. 
    Via MarketBeat

    Performance

    YTD
    +13.33%
    +13.33%
    1 Month
    -9.85%
    -9.85%
    3 Month
    N/A
    N/A
    6 Month
    -1.65%
    -1.65%
    1 Year
    -83.79%
    -83.79%

    More News

    Read More
    Aclaris Therapeutics And 1 Other Stock Under $5 Insiders Are Buying
    Via Benzinga
    $1.8M Bet On This Health Care Stock? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying
    Via Benzinga
    12 Health Care Stocks Moving In Friday's After-Market Session
    Via Benzinga
    Aclaris Therapeutics: Q4 Earnings Insights
    Via Benzinga
    The Analyst Landscape: 4 Takes On Aclaris Therapeutics
    Via Benzinga
    Breaking Down Aclaris Therapeutics: 6 Analysts Share Their Views
    Via Benzinga
    ACRS Stock Earnings: Aclaris Therapeutics Beats EPS, Beats Revenue for Q1 2024
    Via InvestorPlace
    Biotech’s Role in Addressing the Pancreatic Cancer Emergency
    Via FinancialNewsMedia
    Lumen Technologies And 2 Other Stocks Under $2 Insiders Are Buying
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Aclaris Therapeutics' ATI-1777 Faces Uphill Battle In Atopic Dermatitis Treatment Landscape, Analyst Downgrades
    Via Benzinga
    Why CommScope Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Monday's Mid-Day Session
    Via Benzinga
    Why Coherus BioSciences Shares Are Trading Higher By 22%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's Intraday Session
    Via Benzinga
    Why Is Dermatology Focused Aclaris Therapeutics Stock Trading Higher Today?
    Via Benzinga
    Analyst Highlights Aclaris Therapeutics' Encouraging Efficacy For Eczema Candidate, But Cautions On Data Variations
    Via Benzinga
    Crude Oil Falls 1%; Amarin Shares Spike Higher
    Via Benzinga
    Topics Stocks
    Exposures Fossil Fuels US Equities
    Why WD-40 Shares Are Trading Higher By Over 17%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
    Via Benzinga
    12 Health Care Stocks Moving In Wednesday's Intraday Session
    Via Benzinga
    Nasdaq Gains 50 Points; US Crude Inventories Rise Last Week
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Aclaris Therapeutics Shares Fall On Mixed Results From Mid-Stage Eczema Trial
    Via Benzinga
    Dow Surges 100 Points; PriceSmart Earnings Top Views
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    12 Health Care Stocks Moving In Wednesday's Pre-Market Session
    Via Benzinga
    Inflammatory Disease Focused Aclaris Therapeutics Reduces Staff After Failed Psoriatic Arthritis Study
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.